Hepatitis Monthly. 2004; 4 (7): 65-70
in English
| IMEMR
| ID: emr-203598
ABSTRACT
Background and aims:
interferon monotherapy is currently the only approved treatment for chronic hepatitis C [CHC] infection in transfusion dependent thalassemic patients, in whom ribavirin has limited use because of its hematologic complications. Our aim was to evaluate the efficacy and safety of pegylated Interferon monotherapy for the treatment of HCV infection in transfusion dependent thalassemic patients
Search on Google
Index:
IMEMR (Eastern Mediterranean)
Language:
English
Journal:
Hepat. Monthly
Year:
2004
Similar
MEDLINE
...
LILACS
LIS